Bivalent Compounds Degrade EZH2 Protein for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EZH2 inhibitors are ineffective in treating breast cancers with EZH2 overexpression, as they only inhibit the enzymatic activity of EZH2 without affecting protein levels.
Innovation Solution
Development of bivalent compounds that selectively degrade or disrupt EZH2 by conjugating an EZH2 ligand with a degradation/disruption tag, such as thalidomide or adamantane, to recruit the ubiquitination machinery and reduce EZH2 protein levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EZH2 inhibitors are used to treat breast cancer, then the enzymatic activity of EZH2 is inhibited, but the EZH2 protein levels remain unchanged, resulting in treatment inefficacy
Solution Approach 1:
The patent combines two distinct functions into a single bivalent compound: (1) an EZH2-binding moiety that targets and binds to EZH2 protein, and (2) a degradation tag (such as thalidomide or pomalidomide) that recruits the ubiquitin-proteasome system. This merging allows the compound to simultaneously inhibit EZH2 enzymatic activity and promote protein degradation, resolving the contradiction between inhibiting activity and reducing protein levels
Solution Approach 2:
The degradation tag acts as an intermediary that bridges the EZH2-binding moiety and the cellular ubiquitination machinery. The thalidomide-derived tag does not directly degrade EZH2 but instead mediates recruitment of E3 ubiquitin ligases (such as CRL4CRBN), which then tag EZH2 for proteasomal degradation. This intermediary mechanism enables indirect protein level reduction while maintaining targeted specificity
2Object-generated harmful factors
If EZH2 inhibitors are designed to inhibit enzymatic activity, then the methyltransferase function is blocked, but the protein itself remains stable and functional in other contexts
Solution Approach 1:
The patent converts the inherent stability of the EZH2 protein, which normally allows it to persist and continue its harmful enzymatic activity, into a benefit by hijacking the cell's own protein degradation machinery. The degradation tag exploits the ubiquitin-proteasome system's natural function to selectively eliminate EZH2, transforming the protein's stability from a protective feature into a targetable characteristic for therapeutic degradation
3Quantity of substance
If bivalent compounds are developed to degrade EZH2, then protein levels are reduced, but the molecular complexity and design difficulty increase
Solution Approach 1:
The bivalent compound is segmented into two independently optimized modules: an EZH2-binding pharmacophore (such as UNC1999 or EPZ-6438 derivative) and a degradation tag (thalidomide, pomalidomide, or lenalidomide derivative). Each module can be designed and synthesized separately using established medicinal chemistry methods, then combined through linker chemistry. This segmentation reduces overall complexity by allowing modular optimization rather than de novo design of an entirely new complex molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bivalent compounds achieve significant reduction in EZH2 protein levels and enzymatic activity, leading to enhanced therapeutic efficacy in treating EZH2-mediated cancers, including breast cancer.
Implementation Method 1
conjugating an EZH2 ligand with a degradation/disruption tag, such as thalidomide or adamantane, to recruit the ubiquitination machinery and reduce EZH2 protein levels
Data Source
AI summary
Methods for designing bivalent compounds which selectively degrade/disrupt EZH2 and compositions and methods of using such degraders/disruptors to treat EZH2-mediated cancer are provided.